Zoetis Shares Drop Following Earnings Guidance Revision
In its Q2 2026 investor letter, the Impax US Sustainable Economy Fund highlighted Zoetis Inc. (NYSE: ZTS) as a detractor from portfolio performance due to a sharp decline in share price following downward earnings guidance revision. The animal health company is facing challenges with sales of Librela, its key canine arthritis treatment product, which are being hindered by safety concerns among veterinarians. Zoetis closed at $75.81 per share on September 4, 2026, representing a significant drop in value over the past year (-50.04%). The fund cited Zoetis' strong governance and sustainability profile as reasons for its inclusion but noted that near-term product launch delays are extending into next year. Despite these challenges, hedge funds increased their holdings of ZTS from 57 to 64 in Q2 2026. However, the article suggests AI stocks may offer better upside potential and lower downside risk compared to Zoetis.
Tickers: $ZTS
Topics: animal_health portfolio_management sustainable_investing